The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.
 
Pier Franco Conte
Consulting or Advisory Role - Daiichi Sankyo/Lilly; Gilead Sciences; Reveal Genomics
Research Funding - Merck KGaA (Inst)
Patents, Royalties, Other Intellectual Property - HER2Dx patent
Expert Testimony - AstraZeneca
 
Maria Vittoria Dieci
Consulting or Advisory Role - Daiichi Sankyo; Exact Sciences; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Patents, Royalties, Other Intellectual Property - Patent pending HER2DX licensed to University of Padova
 
Giancarlo Bisagni
No Relationships to Disclose
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Bayer; Boehringer Ingelheim; Celgene; Celgene; Eisai; Genentech (Inst); Gilead Sciences Hong Kong; Merck; Novartis; Oncogenex (Inst); Oncogenex (Inst); Pfizer; Puma Biotechnology; Roche; Sanofi; Stemline Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ESMO; SABS
 
Vittoria Fotia
Other Relationship - Daiichi Sankyo; GENTILI; Lilly; Novartis
 
Federico Piacentini
Consulting or Advisory Role - Roche; Seagen
Expert Testimony - Gilead Sciences
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; GENTILI; Lilly; Novartis
Other Relationship - Pfizer
 
Michelino De Laurentiis
Honoraria - GlaxoSmithKline; Lilly; Roche; Seagen; Stemline Therapeutics
Consulting or Advisory Role - Celltrion; Genetic Spa; Gilead Sciences; GlaxoSmithKline; Lilly; Max Farma; Menarini Group; MSD; Novartis; Pfizer; Pierre Fabre; Seagen; Sophos Biotech
Speakers' Bureau - Daiichi Sankyo; Seagen
Research Funding - Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Stemline Therapeutics (Inst)
 
Adolfo G. Favaretto
No Relationships to Disclose
 
Stefano Tamberi
No Relationships to Disclose
 
Giulia Valeria Bianchi
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Lilly; Novartis; Roche; Seagen
 
Claudio Zamagni
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daichi-Sankyo; EISAI; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Lilly; MSD Oncology; Novartis; Pfizer; PharmaMar; Roche; Seagen
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Medivation (Inst); Morphotek (Inst); Novartis (Inst); pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seagen (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichi-Sankyo; Gilead Sciences; Novartis; Pfizer; Roche
 
Saverio Cinieri
No Relationships to Disclose
 
Domenico C. Corsi
No Relationships to Disclose
 
Lucia Del Mastro
Honoraria - Lilly; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Ipsen; Lilly; MSD; Novartis; Olema Oncology; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Olema Oncology; Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Pfizer; Roche
 
Antonella Ferro
Honoraria - AstraZeneca; Daiichi Sankyo; Lilly; MSD; Novartis; Pfizer; Seagen
Travel, Accommodations, Expenses - Gilead Sciences; MSD; Pfizer
 
Alessandra Gennari
Honoraria - Daiichi Sankyo Europe GmbH; Eisai Europe; Gilead Sciences; Lilly; Novartis; Roche
Speakers' Bureau - Eisai Europe
 
Marta Mion
Consulting or Advisory Role - Accord Healthcare; GENTILI; Lilly; Novartis
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Novartis; Seagen; Takeda
 
Antonino Musolino
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Eisai Europe; Lilly; Seagen
Research Funding - Lilly; Roche (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Gian Luca De Salvo
No Relationships to Disclose
 
Valentina Guarneri
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Merck Serono; MSD; Novartis; Olema Oncology; Pierre Fabre
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Lilly; Menarini Steamline; Novartis; Roche; Zentiva
Research Funding - AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Synthon (Inst)
Expert Testimony - Lilly
Travel, Accommodations, Expenses - AstraZeneca; Gilead/Forty Seven